You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

Returns | 1W : 11.6% , 1M : 24.5%,1Y : 84.2%
BOM : 532296     NSE : GLENMARK    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
Apr 22,2021
Price(EOD): Rs. 567.50
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
MarketCap: Rs. 16,014.85 Cr
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
GLENMARK PHARMACEUTICALS 11.6% 24.5% 84.2%
SUN PHARMACEUTICAL INDUSTRIES 2.8% 10.2% 40.1%
DR REDDYS LABORATORIES 7.8% 18.3% 26.4%
DIVIS LABORATORIES 1.7% 12% 63.2%
CIPLA 7.2% 22.8% 58.3%
BIOCON -1.4% 3.4% 14.3%
AUROBINDO PHARMA 8.5% 17.7% 77.9%
LUPIN 5.1% 6.9% 28.9%
TORRENT PHARMACEUTICALS 1.5% 7.8% 15.5%

FUNDAMENTAL ANALYSIS OF GLENMARK PHARMACEUTICALS

 
Fundamentals Score
[Last Annual Data : Mar2020 | TTM
Trailing Twelve Months (TTM) is calculated using last 4 quarterly data and is a good substitute to track Annual results.
Learn More
]
Show Me the Stocks with Fundamentals better than GLENMARK PHARMACEUTICALS Premium


VALUATION OF GLENMARK PHARMACEUTICALS

 
Valuation Score
RatioValue
P/E
P/B
P/S
20.64
P/E Calculated based on EPS of 27.5
[ Mar2020 - Consolidated Results ]

2.64
P/B Calculated based on Book Value of 214.65
[ Mar2020 - Consolidated Results ]

1.5
P/S Calculated based on Revenues of 10662.9 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than GLENMARK PHARMACEUTICALS Premium


FAIR VALUE OF GLENMARK PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
-22%
-49%
-43%

SHARE PRICE MOMENTUM OF GLENMARK PHARMACEUTICALS

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2020
2019
2018
Avg_3yrs
0.27
0.26
0.29
0.27
0.8
0.8
0.9
0.83
[Last Annual Data : Mar2020]

PLEDGED SHARES

Pledged Shares
0 %
As on : Sep2020

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated 1 Qtr Growth 4 Qtr Growth
Revenue
Op Profit
EBIDT
Net Income
-5.61%
4.65%
2.53%
6.06%
1.87%
15.25%
28.41%
30.05%
QtrlyTrend
6
Latest Qtr: Dec2020

GLENMARK PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 3.7% 15.3% 56.9%
S&P BSE MOMENTUM 0.5% 10.6% 36%
S&P BSE MIDSMALLCAP 0.2% 1.7% 80%
S&P BSE 150 MIDCAP 0.1% 1.4% 78.1%
S&P BSE 400 MIDSMALLCAP 0% 1% 81%
S&P BSE MID CAP -0% 0.7% 68.4%
S&P BSE ALLCAP -0.8% -0.3% 59.7%
S&P BSE 500 -0.9% -0.4% 58.8%
S&P BSE 250 LARGEMIDCAP -0.9% -0.4% 57.2%
S&P BSE 200 -1% -0.5% 56.9%
S&P BSE LARGE MIDCAP -1% -0.7% 55.6%
NSE Indices1W1M1Y
NIFTY MID SMALL400 -0.1% 0.9% 80.8%
NIFTY MIDCAP150 -0.3% 0.9% 76.5%
NIFTY FREE MIDCAP 100 -0.4% 1.3% 77.9%
NIFTY MIDCAP 50 -0.9% -2.2% 79.7%
NIFTY 500 -0.9% -0.4% 58.3%
NIFTY LARGE MIDCAP 250 -0.9% -1.7% 65%
NIFTY 200 -1% -0.4% 55.9%

FAQ [Frequently Asked Questions]


Is GLENMARK good for long term investment?

As on 22-Apr-2021, the Fundamentals of GLENMARK are Average and hence you can wait for the results to improve to invest for long term ! See Financial Performance of GLENMARK PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is GLENMARK UnderValued or OverValued?

As on 22-Apr-2021, GLENMARK is Under Valued and hence a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of GLENMARK ?

As on 22-Apr-2021, the Intrinsic Value of GLENMARK is Rs. 999.41 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 726.82
Fair Value [Median EV / Sales Model] : Rs. 1,102.15
Fair Value [Median Price / Sales Model] : Rs. 999.41
Median Fair Value of GLENMARK : Rs. 999.41

Is GLENMARK trading at a Premium or Discount?

As on 22-Apr-2021, GLENMARK is trading at a Discount of -43% based on the Median Intrinsic Value!

Is it right time to buy GLENMARK shares?

As on 22-Apr-2021, GLENMARK is Under Valued and hence a good buying opportunity according to Share Valuation at this time!
The Share Price Momentum is also bullish which indicates strong buying across the board!

What is the Financial Performance of Industry Peers of GLENMARK?

Check out Financials of Industry Peers using below links:
Financials of SUN PHARMACEUTICAL INDUSTRIES LTD
Financials of DR REDDYS LABORATORIES LTD
Financials of DIVIS LABORATORIES LTD
Financials of CIPLA LTD
Financials of BIOCON LTD
Financials of AUROBINDO PHARMA LTD
Financials of LUPIN LTD
Financials of TORRENT PHARMACEUTICALS LTD
Financials of CADILA HEALTHCARE LTD
Financials of ABBOTT INDIA LTD

What are the Frequent Comparisons with GLENMARK?

GLENMARK PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DR REDDYS LABORATORIES LTD
GLENMARK PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD
GLENMARK PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD
GLENMARK PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs BIOCON LTD
GLENMARK PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs AUROBINDO PHARMA LTD
GLENMARK PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs LUPIN LTD
GLENMARK PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs TORRENT PHARMACEUTICALS LTD
GLENMARK PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CADILA HEALTHCARE LTD
GLENMARK PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ABBOTT INDIA LTD

Open Demat Account & Start Investing
    Affiliate Links

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z